Teva Announces Final Approval of Generic Hyzaar® and Cozaar®

07.04.2010 - 16:40 Uhr - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium). As the first company to file ANDAs that contained a paragraph IV certification for Hyzaar® and Cozaar®: Teva has been awarded 180-day Hatch-Waxman statutory exclusivity to market these products. The brand products had combined annual sales of approximately $1.6 billion in the United States, based on IMS...